145 related articles for article (PubMed ID: 37920752)
21. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.
Bonnick S; Broy S; Kaiser F; Teutsch C; Rosenberg E; DeLucca P; Melton M
Curr Med Res Opin; 2007 Jun; 23(6):1341-9. PubMed ID: 17594775
[TBL] [Abstract][Full Text] [Related]
22. Effect of alendronate treatment on bone mineral density in male patients with osteoporosis.
Drake AJ; Brietzke SA; Aprill BS; Shakir KM
Endocr Pract; 1999; 5(4):184-90. PubMed ID: 15251673
[TBL] [Abstract][Full Text] [Related]
23. Associations of polymorphisms in the SOST gene and bone mineral density in postmenopausal Chinese Women.
Zhang H; He JW; Wang C; Zhang Z; Yue H; Hu WW; Gu JM; Hu YQ; Li M; Fu WZ; Zhang ZL
Osteoporos Int; 2014 Dec; 25(12):2797-803. PubMed ID: 25103216
[TBL] [Abstract][Full Text] [Related]
24. Influence of type 2 diabetes mellitus on bone mineral density response to bisphosphonates in late postmenopausal osteoporosis.
Dagdelen S; Sener D; Bayraktar M
Adv Ther; 2007; 24(6):1314-20. PubMed ID: 18165214
[TBL] [Abstract][Full Text] [Related]
25. The effect of vitamin D receptor BsmI genotype on the response to osteoporosis treatment in postmenopausal women: a pilot study.
Creatsa M; Pliatsika P; Kaparos G; Antoniou A; Armeni E; Tsakonas E; Panoulis C; Alexandrou A; Dimitraki E; Christodoulakos G; Lambrinoudaki I
J Obstet Gynaecol Res; 2011 Oct; 37(10):1415-22. PubMed ID: 21651652
[TBL] [Abstract][Full Text] [Related]
26. Determinants of one-year response of lumbar bone mineral density to alendronate treatment in elderly Japanese women with osteoporosis.
Iwamoto J; Takeda T; Sato Y; Uzawa M
Yonsei Med J; 2004 Aug; 45(4):676-82. PubMed ID: 15344210
[TBL] [Abstract][Full Text] [Related]
27. The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.
Tascioglu F; Colak O; Armagan O; Alatas O; Oner C
Rheumatol Int; 2005 Nov; 26(1):21-9. PubMed ID: 15688191
[TBL] [Abstract][Full Text] [Related]
28. Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -international.
Reid DM; Hosking D; Kendler D; Brandi ML; Wark JD; Weryha G; Marques-Neto JF; Gaines KA; Verbruggen N; Melton ME
Clin Drug Investig; 2006; 26(2):63-74. PubMed ID: 17163237
[TBL] [Abstract][Full Text] [Related]
29. The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density.
Fitzpatrick LA; Dabrowski CE; Cicconetti G; Gordon DN; Papapoulos S; Bone HG; Bilezikian JP
J Clin Endocrinol Metab; 2011 Aug; 96(8):2441-9. PubMed ID: 21593114
[TBL] [Abstract][Full Text] [Related]
30. Forearm bone mineral densitometry cannot be used to monitor response to alendronate therapy in postmenopausal women.
Bouxsein ML; Parker RA; Greenspan SL
Osteoporos Int; 1999; 10(6):505-9. PubMed ID: 10663352
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and tolerability of alendronate once weekly in Asian postmenopausal osteoporotic women.
Ho AY; Kung AW
Ann Pharmacother; 2005 Sep; 39(9):1428-33. PubMed ID: 16076919
[TBL] [Abstract][Full Text] [Related]
32. Benefit period using alendronate to increase bone mineral density in women with osteoporosis?
Ozdemir F; Rodoplu M
Chin Med J (Engl); 2005 Mar; 118(5):383-90. PubMed ID: 15780207
[TBL] [Abstract][Full Text] [Related]
33. Association Between Geranylgeranyl Pyrophosphate Synthase Gene Polymorphisms and Bone Phenotypes and Response to Alendronate Treatment in Chinese Osteoporotic Women.
Han LW; Ma DD; Xu XJ; Lü F; Liu Y; Xia WB; Jiang Y; Wang O; Xing XP; Li M
Chin Med Sci J; 2016 Mar; 31(1):8-16. PubMed ID: 28031082
[TBL] [Abstract][Full Text] [Related]
34. Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with 1-year response of lumbar bone mineral density to alendronate in postmenopausal Japanese women with osteoporosis.
Iwamoto J; Takeda T; Sato Y; Uzawa M
J Bone Miner Metab; 2005; 23(3):238-42. PubMed ID: 15838627
[TBL] [Abstract][Full Text] [Related]
35. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis.
Devogelaer JP; Broll H; Correa-Rotter R; Cumming DC; De Deuxchaisnes CN; Geusens P; Hosking D; Jaeger P; Kaufman JM; Leite M; Leon J; Liberman U; Menkes CJ; Meunier PJ; Reid I; Rodriguez J; Romanowicz A; Seeman E; Vermeulen A; Hirsch LJ; Lombardi A; Plezia K; Santora AC; Yates AJ; Yuan W
Bone; 1996 Feb; 18(2):141-50. PubMed ID: 8833208
[TBL] [Abstract][Full Text] [Related]
36. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.
Rosen CJ; Hochberg MC; Bonnick SL; McClung M; Miller P; Broy S; Kagan R; Chen E; Petruschke RA; Thompson DE; de Papp AE;
J Bone Miner Res; 2005 Jan; 20(1):141-51. PubMed ID: 15619680
[TBL] [Abstract][Full Text] [Related]
37. SOST polymorphisms and response to alendronate treatment in postmenopausal Chinese women with osteoporosis.
Zhou PR; Xu XJ; Zhang ZL; Liao EY; Chen DC; Liu J; Wu W; Jiang Y; Wang O; Xia WB; Xing XP; Xu L; Li M
Pharmacogenomics; 2015; 16(10):1077-88. PubMed ID: 26250343
[TBL] [Abstract][Full Text] [Related]
38. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.
Planas J; Trilla E; Raventós C; Cecchini L; Orsola A; Salvador C; Placer J; Encabo G; Morote J
BJU Int; 2009 Dec; 104(11):1637-40. PubMed ID: 19549260
[TBL] [Abstract][Full Text] [Related]
39. Effects of alendronate combined with hormone replacement therapy on osteoporotic postmenopausal Chinese women.
Tseng LN; Sheu WH; Ho ES; Lan HH; Hu CC; Kao CH
Metabolism; 2006 Jun; 55(6):741-7. PubMed ID: 16713432
[TBL] [Abstract][Full Text] [Related]
40. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
